-        Third approved indication for SKYRIZI® (risankizumab) and the first specific IL-23 inhibitor for the treatment of Crohn's disease in the European Union (EU)
-        A significantly higher proportion of patients on SKYRIZI achieved clinical remission, endoscopic response, mucosal healing and endoscopic remission at week 12 in induction studies compared to placebo1,2,3
-        A significantly higher proportion of patients achieved clinical remission and endoscopic response at week 52 with SKYRIZI maintenance1,2,3
-        Crohn's disease is a chronic, systemic inflammatory disease that manifests as inflammation within the gastrointestinal tract, causing persistent diarrhea, abdominal pain and can require urgent medical care4,5,6

NORTH CHICAGO, Ill., Nov. 21, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application for epcoritamab (DuoBody®-CD3xCD20), an investigational subcutaneous bispecific antibody, for the treatment of adult patients with relapsed/refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy.

NORTH CHICAGO, Ill., Nov. 8, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it would present new data across its rheumatology portfolio, including RINVOQ® (upadacitinib) for rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis, and SKYRIZI® (risankizumab) for psoriasis and psoriatic arthritis at the American College of Rheumatology's annual meeting (ACR Convergence 2022) taking place November 10-14 in Philadelphia, PA, as well as virtually.

NORTH CHICAGO, Ill., Oct. 24, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that 26 abstracts across its gastroenterology portfolio will be presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting, October 21-26, 2022, in Charlotte, N.C., and virtually.

NORTH CHICAGO, Ill., Oct. 21, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announces that the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib 15 mg, once daily), an oral therapy, for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation who have had an inadequate response or intolerance to tumor necrosis factor (TNF) blocker therapy. This additional indication follows the FDA approval of RINVOQ in April of this year for adults with active ankylosing spondylitis (AS) who have had an inadequate response or intolerance to one or more TNF blockers, making it the first and only JAK inhibitor that is approved for both conditions.1

Patients of color can face challenges when seeking care for skin conditions. See how we’re partnering with the dermatology community to help drive change.

NORTH CHICAGO, Ill., Sept. 29, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today revealed the spectrum of new data from studies of risankizumab (SKYRIZI®) in Crohn's disease and upadacitinib (RINVOQ®) in ulcerative colitis and Crohn's disease that will be presented as live presentations and e-Posters at the United European Gastroenterology (UEG) Week 2022, October 8-11 in Vienna and online. In total, AbbVie is presenting 17 abstracts across a broad range of studies in inflammatory bowel disease (IBD).

CHMP positive opinion is based on results from three Phase 3 studies: two for induction and one for maintenance1,2
Crohn's disease is a chronic, systemic disease that manifests as inflammation within the gastrointestinal tract, causing persistent diarrhea, abdominal pain and can require urgent medical care3,4
If approved, risankizumab will be the first specific IL-23 inhibitor for the treatment of Crohn's disease in the European Union (EU)
The European Commission decision is expected in the fourth quarter of 2022. This anticipated approval would mark the third indication for risankizumab in the EU

- Analyses included 100-week efficacy and safety data from the four-year, open-label extension period of KEEPsAKE 1 and 2 evaluating SKYRIZI in patients with active psoriatic arthritis1

NORTH CHICAGO, Ill., Sept. 8, 2022 /PRNewswire/ -- An analysis from AbbVie's (NYSE: ABBV) three-year, 28-country MEASURE-AD study revealed that people living with moderate to severe atopic dermatitis (an immune-mediated skin disease) who are not receiving systemic therapy had greater clinical, psychosocial and economic burdens compared to those receiving systemic therapy.1 A separate analysis from the MEASURE-AD study demonstrated that better quality of life – as measured by Dermatology Life Quality Index (DLQI) scores – and lower disease severity scores were associated with lower clinical burden and work impairment.2 Results from the MEASURE-AD subanalyses were featured at the 31st European Academy of Dermatology and Venereology (EADV) Hybrid Congress onsite in Milan and online from September 7-10 as a poster and an oral presentation.